Durable engraftment of genetically modified FVIII‐secreting autologous bone marrow stromal cells in the intramedullary microenvironment
Open Access
- 23 April 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (7) , 3698-3702
Abstract
Genetically modified FVIII‐expressing autologous bone marrow‐derived mesenchymal stromal cells (BMSCs) could cure haemophilia A. However, culture‐expanded BMSCs engraft poorly in extramedullary sites. Here, we compared the intramedullary cavity, skeletal muscle, subcutaneous tissue and systemic circulation as tissue microenvironments that could support durable engraftment of FVIII‐secreting BMSC in vivo. A zinc finger nuclease integrated human FVIII transgene into PPP1R12C (intron 1) of culture‐expanded primary canine BMSCs. FVIII‐secretory capacity of implanted BMSCs in each dog was expressed as an individualized therapy index (number of viable BMSCs implanted × FVIII activity secreted/million BMSCs/24 hours). Plasma samples before and after implantation were assayed for transgenic FVIII protein using an anti‐human FVIII antibody having negligible cross‐reactivity with canine FVIII. Plasma transgenic FVIII persisted for at least 48 weeks after implantation in the intramedullary cavity. Transgenic FVIII protein levels were low after intramuscular implantation and undetectable after both intravenous infusion and subcutaneous implantation. All plasma samples were negative for anti‐human FVIII antibodies. Plasma concentrations and durability of transgenic FVIII secretion showed no correlation with the therapy index. Thus, the implantation site microenvironment is crucial. The intramedullary microenvironment, but not extramedullary tissues, supported durable engraftment of genetically modified autologous FVIII‐secreting BMSCs.Keywords
Funding Information
- National Medical Research Council (CIRG/1326 2012)
This publication has 15 references indexed in Scilit:
- Characterization of Insulin-Secreting Porcine Bone Marrow Stromal Cells Ex Vivo and Autologous Cell Therapy in VivoCell Transplantation, 2015
- The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapiesMolecular Immunology, 2014
- Intragenic integration in DLC1 sustains factor VIII expression in primary human cells without insertional oncogenicityGene Therapy, 2014
- Mesenchymal stem cells contribute to endogenous FVIII:c productionJournal of Cellular Physiology, 2012
- Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cellsBMC Veterinary Research, 2012
- Optimizing outcomes for patients with severe haemophilia AHaemophilia, 2007
- Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartmentBlood, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene TherapyNew England Journal of Medicine, 2002
- Baboon Mesenchymal Stem Cells Can Be Genetically Modified to Secrete Human Erythropoietin In VivoHuman Gene Therapy, 2001